Join our daily newsletter At The Bell to receive exclusive market insights
- Molecular diagnostics company Genetic Technologies (GTG) has appointed Simon Morriss as Chief Executive Officer as of February 2021
- Genetic Technologies offer predictive testing and assessment tools to empower physicians to proactively manage patient health
- Along with a fixed salary of $350,000, Simon Morriss will be eligible to receive 60 million performance rights on commencement for nil consideration, subject to GTG’s share price reaching $0.016 or greater for more than 15 consecutive ASX trading days
- Additionally, the board has announced George Muchnicki will be stepping into the role of Chief Medical Officer and Executive Director
- Genetic Technologies shares are up 6.67 per cent, trading at 0.8 cents per share
Molecular diagnostics company Genetic Technologies (GTG) has appointed Simon Morriss as Chief Executive Officer, commencing February 2021.
Genetic Technologies offer predictive testing and assessment tools to empower physicians to proactively manage patient health.
The CEO role comes with a fixed salary of $350,000 and makes Morriss eligible to receive up to 30 per cent of the total employment package (inclusive of superannuation) if specific company and personal performance hurdles are met.
The position also makes the CEO eligible to receive 60 million performance rights on commencement for nil consideration, subject to GTG’s share price reaching $0.016 (or the equivalent in the case of a stock split or stock consolidation), or greater for more than 15 consecutive ASX trading days.
Simon Moriss has over 20 years of experience within the pharmaceutical and healthcare industries, having previously held senior executive positions at Sanofi and Blackmores (BKL).
“We are pleased to appoint Simon Morriss to the role of CEO. His extensive experience in commercialising products within the pharmaceutical and healthcare industry will be critical for Genetic Technologies as we move from a predominantly research-based business to expanding our commercialisation efforts,” Chairman Peter Rubinstein said.
Additionally, the board has announced George Muchnicki, acting CEO since September 2019, will be stepping into the role of Chief Medical Officer and Executive Director.
In his role as Chief Medical Officer, George will continue to leverage his exceptional background and experience to continue to advance the product development and establish the medical framework for GTGs platform offering.
Genetic Technologies shares are up 6.67 per cent, trading at 0.8 cents per share as at 1:20 pm AEDT.
